164 related articles for article (PubMed ID: 10889554)
1. Hippocampal synaptic pathology in schizophrenia, bipolar disorder and major depression: a study of complexin mRNAs.
Eastwood SL; Harrison PJ
Mol Psychiatry; 2000 Jul; 5(4):425-32. PubMed ID: 10889554
[TBL] [Abstract][Full Text] [Related]
2. Preferential involvement of excitatory neurons in medial temporal lobe in schizophrenia.
Harrison PJ; Eastwood SL
Lancet; 1998 Nov; 352(9141):1669-73. PubMed ID: 9853440
[TBL] [Abstract][Full Text] [Related]
3. Decreased expression of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia: further evidence for a synaptic pathology affecting glutamate neurons.
Eastwood SL; Harrison PJ
Schizophr Res; 2005 Mar; 73(2-3):159-72. PubMed ID: 15653259
[TBL] [Abstract][Full Text] [Related]
4. Reduced spinophilin but not microtubule-associated protein 2 expression in the hippocampal formation in schizophrenia and mood disorders: molecular evidence for a pathology of dendritic spines.
Law AJ; Weickert CS; Hyde TM; Kleinman JE; Harrison PJ
Am J Psychiatry; 2004 Oct; 161(10):1848-55. PubMed ID: 15465982
[TBL] [Abstract][Full Text] [Related]
5. Expression of complexin I and II mRNAs and their regulation by antipsychotic drugs in the rat forebrain.
Eastwood SL; Burnet PW; Harrison PJ
Synapse; 2000 Jun; 36(3):167-77. PubMed ID: 10819897
[TBL] [Abstract][Full Text] [Related]
6. Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a Western blot study of synaptophysin, GAP-43 and the complexins.
Eastwood SL; Harrison PJ
Brain Res Bull; 2001 Jul; 55(5):569-78. PubMed ID: 11576753
[TBL] [Abstract][Full Text] [Related]
7. Hippocampal complexin proteins and cognitive dysfunction in schizophrenia.
Sawada K; Barr AM; Nakamura M; Arima K; Young CE; Dwork AJ; Falkai P; Phillips AG; Honer WG
Arch Gen Psychiatry; 2005 Mar; 62(3):263-72. PubMed ID: 15753239
[TBL] [Abstract][Full Text] [Related]
8. Vesicular glutamate transporter mRNA expression in the medial temporal lobe in major depressive disorder, bipolar disorder, and schizophrenia.
Uezato A; Meador-Woodruff JH; McCullumsmith RE
Bipolar Disord; 2009 Nov; 11(7):711-25. PubMed ID: 19839996
[TBL] [Abstract][Full Text] [Related]
9. Cerebellar synaptic protein expression in schizophrenia.
Eastwood SL; Cotter D; Harrison PJ
Neuroscience; 2001; 105(1):219-29. PubMed ID: 11483314
[TBL] [Abstract][Full Text] [Related]
10. Decreased mRNA expression of netrin-G1 and netrin-G2 in the temporal lobe in schizophrenia and bipolar disorder.
Eastwood SL; Harrison PJ
Neuropsychopharmacology; 2008 Mar; 33(4):933-45. PubMed ID: 17507910
[TBL] [Abstract][Full Text] [Related]
11. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia.
Eastwood SL; Burnet PW; Harrison PJ
Neuroscience; 1995 May; 66(2):309-19. PubMed ID: 7477874
[TBL] [Abstract][Full Text] [Related]
12. Altered immunoreactivity of complexin protein in prefrontal cortex in severe mental illness.
Sawada K; Young CE; Barr AM; Longworth K; Takahashi S; Arango V; Mann JJ; Dwork AJ; Falkai P; Phillips AG; Honer WG
Mol Psychiatry; 2002; 7(5):484-92. PubMed ID: 12082566
[TBL] [Abstract][Full Text] [Related]
13. Common proteomic changes in the hippocampus in schizophrenia and bipolar disorder and particular evidence for involvement of cornu ammonis regions 2 and 3.
Föcking M; Dicker P; English JA; Schubert KO; Dunn MJ; Cotter DR
Arch Gen Psychiatry; 2011 May; 68(5):477-88. PubMed ID: 21536977
[TBL] [Abstract][Full Text] [Related]
14. Altered prefrontal cortical MARCKS and PPP1R9A mRNA expression in schizophrenia and bipolar disorder.
Konopaske GT; Subburaju S; Coyle JT; Benes FM
Schizophr Res; 2015 May; 164(1-3):100-8. PubMed ID: 25757715
[TBL] [Abstract][Full Text] [Related]
15. In vivo hippocampal subfield volumes in schizophrenia and bipolar disorder.
Haukvik UK; Westlye LT; Mørch-Johnsen L; Jørgensen KN; Lange EH; Dale AM; Melle I; Andreassen OA; Agartz I
Biol Psychiatry; 2015 Mar; 77(6):581-8. PubMed ID: 25127742
[TBL] [Abstract][Full Text] [Related]
16. Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression.
Fatemi SH; Earle JA; McMenomy T
Mol Psychiatry; 2000 Nov; 5(6):654-63, 571. PubMed ID: 11126396
[TBL] [Abstract][Full Text] [Related]
17. Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder.
Gaughran F; Payne J; Sedgwick PM; Cotter D; Berry M
Brain Res Bull; 2006 Jul; 70(3):221-7. PubMed ID: 16861106
[TBL] [Abstract][Full Text] [Related]
18. Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders.
Thompson Ray M; Weickert CS; Wyatt E; Webster MJ
J Psychiatry Neurosci; 2011 May; 36(3):195-203. PubMed ID: 21223646
[TBL] [Abstract][Full Text] [Related]
19. Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia.
Heckers S; Stone D; Walsh J; Shick J; Koul P; Benes FM
Arch Gen Psychiatry; 2002 Jun; 59(6):521-9. PubMed ID: 12044194
[TBL] [Abstract][Full Text] [Related]
20. Interplay between childhood trauma and BDNF val66met variants on blood BDNF mRNA levels and on hippocampus subfields volumes in schizophrenia spectrum and bipolar disorders.
Aas M; Haukvik UK; Djurovic S; Tesli M; Athanasiu L; Bjella T; Hansson L; Cattaneo A; Agartz I; Andreassen OA; Melle I
J Psychiatr Res; 2014 Dec; 59():14-21. PubMed ID: 25246365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
